Villepinte, November 17th, 2025: GUERBET (FR0000032526 GBT):

At the upcoming RSNA (Radiological Society of North America) in Chicago, from November 30 to December 4, 2025, Guerbet reaffirms its commitment to innovation in medical imaging, advance training, and international collaboration.

This year, Guerbet will showcase Elucirem™ (Gadopiclenol), our macrocyclic gadolinium-based contrast agent. With its high relaxivity and exceptional stability, Elucirem™ delivers image quality comparable to currently available macrocyclic gadolinium-based agents, while using half the amount of active ingredient. This breakthrough reflects Guerbet’s ambition to provide solutions that are both high-performing and responsible, serving healthcare professionals and patients alike.

In addition, an exhibition of patient cases will highlight the critical role of Real-World Evidence (RWE) in advancing radiology practices, demonstrating how real-life data helps improve patient care and guide clinical decision-making.

Our Open Theater will host interactive sessions focused on key topics such as increasing relaxivity and reducing gadolinium doses, the impact of volume and concentration in GBCA administration, and essential updates on contrast agent safety.

Finally, with France as the RSNA 2025 Country of Honor, Guerbet is proud to welcome the French Pavilion on its booth, dedicated to members of French Healthcare, to foster dialogue and cooperation around innovative health solutions. French Healthcare is an initiative that brings together companies, institutions, and healthcare stakeholders to promote French medical and technological excellence worldwide. Learn more at www.frenchhealthcare.fr.

Learn more at: www.frenchhealthcare.fr.

Meet Guerbet at RSNA 2025:
📍 South Hall Booth #1747 // McCormick Place, Chicago
📅 November 30 – December 4, 2025

For more information about our innovations and commitments: www.guerbet.com

About Guerbet

At Guerbet, we build lasting connections to enable better living. This is our Purpose. We are a global leader in medical imaging, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging.

Pioneers in contrast agents for 98 years, with 2,905 employees worldwide, we continuously innovate and dedicate 9% of our revenue to Research & Development across four centers in France and the United States. Guerbet (GBT) is listed on Euronext Paris, Compartment B, and achieved €841 million in revenue in 2024.

For more information, please visit www.guerbet.com.

Contact :

Matthieu BRUNEAU - Global corporate communication manager 

Email : [email protected]

Phone : +33 6 78 83 89 96